Manulife (Manufacturers Life Insurance)
ABUS icon

Manulife (Manufacturers Life Insurance)’s Arbutus Biopharma ABUS Stock Holding History

Manulife (Manufacturers Life Insurance)’s Portfolio ABUS Stock Details ABUS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$191K Sell
42,429
-5,030
-11% -$22K ﹤0.01% 2475
2025
Q4 		$228K Sell
47,459
-6,702
-12% -$30.1K ﹤0.01% 2464
2025
Q3 		$246K Sell
54,161
-5,189
-9% -$19.1K ﹤0.01% 2475
2025
Q2 		$183K Buy
59,350
+3,540
+6% +$11.8K ﹤0.01% 2590
2025
Q1 		$195K Buy
55,810
+315
+0.6% +$1.05K ﹤0.01% 2507
2024
Q4 		$181K Sell
55,495
-57
-0.1% -$210 ﹤0.01% 2662
2024
Q3 		$214K Sell
55,552
-1,771
-3% -$6.79K ﹤0.01% 2637
2024
Q2 		$177K Buy
57,323
+4,191
+8% +$12.6K ﹤0.01% 2650
2024
Q1 		$137K Buy
53,132
+965
+2% +$2.5K ﹤0.01% 2707
2023
Q4 		$130K Hold
52,167
– – ﹤0.01% 2746
2023
Q3 		$106K Hold
52,167
– – ﹤0.01% 2787
2023
Q2 		$120K Buy
52,167
+10,006
+24% +$26K ﹤0.01% 2779
2023
Q1 		$128K Hold
42,161
– – ﹤0.01% 2690
2022
Q4 		$98.2K Buy
42,161
+168
+0.4% +$402 ﹤0.01% 2802
2022
Q3 		$80.2K Sell
41,993
-1,720
-4% -$4.05K ﹤0.01% 2860
2022
Q2 		$118K Buy
43,713
+7,629
+21% +$19.5K ﹤0.01% 2852
2022
Q1 		$108K Sell
36,084
-6,901
-16% -$21.1K ﹤0.01% 2947
2021
Q4 		$167 Sell
42,985
-3,219
-7% -$12.5K ﹤0.01% 2957
2021
Q3 		$198K Sell
46,204
-2,661
-5% -$8.87K ﹤0.01% 2990
2021
Q2 		$148K Buy
+48,865
New +$151K ﹤0.01% 3192
2019
Q2 		– Sell
-26,188
Closed -$93K – 2901
2019
Q1 		$93K Buy
26,188
+15,296
+140% +$58.7K ﹤0.01% 2584
2018
Q4 		$42K Sell
10,892
-12,614
-54% -$62.1K ﹤0.01% 2490
2018
Q3 		$223K Sell
23,506
-6,390
-21% -$63.4K ﹤0.01% 2703
2018
Q2 		$218K Buy
+29,896
New +$178K ﹤0.01% 3057

Other funds holding ABUS

Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
TSC
Two Seas Capital Rye, New York $7.15B AUM 169.27% 1-Year Est. Return
WCM
Whitefort Capital Management New York $339M AUM 52.48% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
RCMNY
Rubric Capital Management (New York) New York $9.44B AUM 68.42% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Barclays
Barclays London, United Kingdom $416B AUM 33.63% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
ACM
ADAR1 Capital Management Austin, Texas $1.7B AUM 340.85% 1-Year Est. Return

Manulife (Manufacturers Life Insurance)'s ABUS Position: Q1 2026 in Review

Manulife (Manufacturers Life Insurance) reduced its Arbutus Biopharma (ABUS) stake by 11% in Q1 2026, selling an estimated $22K and leaving 42,429 shares worth $191K. The position accounts for ﹤0.01% of the portfolio, ranked #2475.

Manulife (Manufacturers Life Insurance) first reported a position in ABUS in Q2 2018 and has held it in 24 quarters since. The position peaked at $246K in Q3 2025. 167 funds tracked by Wall St. Rank hold ABUS as of Q1 2026.

  • Manulife (Manufacturers Life Insurance) held 42,429 shares of Arbutus Biopharma worth $191K as of Q1 2026.
  • Manulife (Manufacturers Life Insurance) sold 5,030 Arbutus Biopharma shares in Q1 2026, an estimated $22K.
  • Arbutus Biopharma made up ﹤0.01% of Manulife (Manufacturers Life Insurance)'s portfolio in Q1 2026, its #2475 holding.
  • Manulife (Manufacturers Life Insurance) first reported a position in Arbutus Biopharma in Q2 2018 and has held it in 24 quarters since.
  • Manulife (Manufacturers Life Insurance)'s Arbutus Biopharma position peaked at $246K in Q3 2025.
  • 167 funds tracked by Wall St. Rank held Arbutus Biopharma as of Q1 2026.

Based on Manulife (Manufacturers Life Insurance)'s 13F filing for Q1 2026, filed 15 May 2026.